Growth hormone / visceral fat
Tesamorelin
Egrifta (GHRH analog)
FDA-approved
Based on expert consensus from publicly available videos plus public FDA/regulatory status — not medical advice. Peptides are prescription territory; consult a physician before using anything here.
The Verdict
The clearest FDA-approved growth-hormone peptide (Koniver via Huberman) — approved to cut visceral fat. Still a prescription drug with GH-related cautions, not a casual longevity add-on.
The Evidence
FDA / Legal Status
FDA-approved to reduce visceral fat (HIV-associated lipodystrophy)
Human Evidence
Human trials behind approval; a GHRH analog that raises GH more physiologically
Sport / Doping
Prescription drug; banned in sport
Safety Flags
- Raising growth hormone carries cancer risk; not for people with active malignancy
- Lower GH/IGF-1 after midlife is associated with longevity — GH-boosting in older adults may be counterproductive
Who Covers It
Other experts in the panel had no substantive coverage of this peptide — we don't guess their position.
Want the deep dive on Tesamorelin?
This grade is free. Pro unlocks chat with the full expert dataset — ask about dosing, stacks, sourcing, and the exact citations behind every claim.
Cancel anytime